Results 71 to 80 of about 226,651 (317)

Evaluation of Xpert® MTB/RIF and ustar easyNAT™ TB IAD for diagnosis of tuberculous lymphadenitis of children in Tanzania : a prospective descriptive study [PDF]

, 2016
Fine needle aspiration biopsy has become a standard approach for diagnosis of peripheral tuberculous lymphadenitis. The aim of this study was to compare the performance of Xpert MTB/RIF and Ustar EasyNAT TB IAD nucleic acid amplification assays, against ...
AT Cruz, CA Wright, CA Wright, CA Wright, CC Anunobi, CC Boehme, CJL Murray, CM Denkinger, CM Denkinger, CM Perez-Velez, D Hillemann, E Penz, Edward Masika, ES Cibas, F Ardito, FA Mhimbira, Hans-Peter Beck, Hassan Chande, J Ayugi, J Cohen, JA Seddon, JB Reitsma, Klaus Reither, L Coetzee, Levan Jugheli, M Pai, Maira Bholla, Mohamed Sasamalo, Neema Kapalata, PJ Dodd, R Fang, RR Kazwala, S Chakravorty, SGM Mfinanga, SH Siddiqi, SM Newton, Tracy R. Glass, Ustar Biotechnologies, World Health Organization, X Ou   +39 more
core   +3 more sources

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Tuberculosis contact tracing among children and adolescent referred to children's hospital in Rio de Janeiro, Brazil

Brazilian Journal of Infectious Diseases, 2015
Objective: To describe the investigation of latent tuberculosis infection and indication for isoniazid preventive therapy in children and adolescents evaluated at the children's hospital. Methods: This retrospective study examines all latent tuberculosis
Angela Marcia Cabral Mendonça, Afrânio Lineu Kritski, Clemax Couto Sant’Anna   +2 more
doaj   +1 more source

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges

Advanced Healthcare Materials, EarlyView.
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla   +3 more
wiley   +1 more source

Latent tuberculosis infection in patients with rheumatic diseases

Jornal Brasileiro de Pneumologia, 2019
Most people infected by Mycobacterium tuberculosis (Mtb) do not have any signs or disease symptoms, a condition known as latent tuberculosis infection (LTBI).
Camila Anton, F. D. Machado, Jorge Mario Ahumada Ramirez, Rafaela Manzoni Bernardi, P. Palominos, C. Brenol, F. Mello, D. Silva   +7 more
semanticscholar   +1 more source

A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications

Advanced Science, EarlyView.
ImmuDef, a novel algorithm to quantitatively evaluate the anti‐infection immune defense function of an individual based on RNA‐seq data via a variational autoencoder (VAE) model. It is validated on 3200+ samples across four immune states with high accuracy. It can serve as a metric for disease severity and prognosis across pathogenic cohorts.
Zhen‐Lin Tan, Tao Luo, Yu Lin, Xiao‐Jun Wu, Wen‐Kang Shen, Jie Chen, Qian Lei, An‐Yuan Guo   +7 more
wiley   +1 more source

Association between hematological inflammatory markers and latent TB infection: insights from NHANES 2011–2012 and transcriptomic data

Frontiers in Cellular and Infection Microbiology
BackgroundLatent tuberculosis infection affects about one-quarter of the global population and can progress to active tuberculosis. Hematological inflammatory markers, such as the systemic immune-inflammation index, neutrophil-to-lymphocyte ratio ...
Yang Liu, Chunyan He, He Zhao, Weiyao Zhong, Shihua Sun, Zhuo Li, Jingwei Shi   +6 more
doaj   +1 more source

Establishment of a biosafe murine model of skeletal tuberculosis using Mycobacterium smegmatis

Animal Models and Experimental Medicine, EarlyView.
This study developed a biosafe, accessible, and versatile murine model of bone TB using Mycobacterium smegmatis, a fast‐growing, nonpathogenic mycobacterial species with high genomic homology to Mycobacterium tuberculosis. Three infection routes—subperiosteal calvarial injection, intratibial injection, and intracardiac (left ventricular) inoculation ...
Yewei Jia, Yuhuai Guo, Yusheng Yang, Jie Zhang, Ziyang Zhang, Ying Qu, Jiulin Tan, Jie Shen, Nathachit Limjunyawong, Jianzhong Xu, Zehua Zhang, Fei Luo, Ce Dou   +12 more
wiley   +1 more source

Prevalence and Risk Factors of Latent Tuberculosis Infection (LTBI) at Madura Boarding School as a High-Risk Congregate Setting

Juxta: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Introduction: Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a highly contagious airborne disease. High-risk environments with frequent close interactions contribute to the spread of TB.
Muhammad Arif Ananto, Retno Asih Setyoningrum, Pudji Lestari   +2 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source